Merck’s Phase 3 Study Reveals Successful Outcomes for Subcutaneous Pembrolizumab with Berahyaluronidase Alfa
Merck, recognized as MSD outside the United States and Canada, has announced encouraging topline outcomes from the pivotal phase 3 MK-3475A-D77 study. This investigation is analyzing whether the subcutaneous delivery of pembrolizumab—a renowned anti-PD-1 therapy by Merck, commercially known as […]